118 results on '"Victoria Potter"'
Search Results
2. HAPLOIDENTICAL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS: THE ROLE OF PREVIOUS LINES OF THERAPY.
- Author
-
Daniele Avenoso, Fabio Serpenti, Liron Barnea Slonim, Styliani Bouziana, Francesco Dazzi, Guy Hannah, Michelle Kenyon, Varun Mehra, Austin Kulasekararaj, Pramila Krishnamurthy, Mili Naresh Shah, Sharon Lionel, Antonio Pagliuca, and Victoria Potter
- Subjects
Haplo-identical stem cell transplantation ,AML ,MDS ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: Allogeneic haematopoietic stem-cell transplant is a potentially curative option for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for selection of haploidentical donors in patients who are eligible for the procedure, but do not have a fully matched donor, since it can overcome the HLA barrier. There is still an active debate on whether intensification of the conditioning regimen is necessary with haploidentical donors when peripheral blood stem cells are used as the source of the graft. Herein we report our decennial experience of haploidentical stem-cell transplant using peripheral blood stem cells at King’s College Hospital. Objectives: The primary objective was to evaluate overall survival (OS) for patients with less than two previous lines of therapy. Secondary objectives were total OS, OS according to cytomegalovirus (CMV) reactivation, incidence of transplant-related mortality (TRM), graft-versus-host disease (GVHD) and GVHD-relapse-free survival (GRFS). Results: One-year and three-year total OS were 62% and 43%, respectively, with a median OS of 22 months. One-year and three-year OS for patients with ≤2 and in patients with >2 previous lines of therapy were 72% and 55%, and 60% and 22%, respectively (p-value=0.04). The median OS in patients with >2 previous lines of therapy and ≤2 lines of therapy was 16 and 49 months, respectively. Cumulative incidence (CI) of relapse was 25% with a median time to relapse of 5 months (range 1 – 38 months). Conclusions: Haploidentical haematopoietic stem-cell transplant is potentially curative in chemo-sensitive AML and MDS and offers a high rate of prolonged remission. Our cohort further confirms the role of consolidative haploidentical transplant in patients in complete remission and highlights that patients with heavily pre-treated disease may not benefit from this strategy.
- Published
- 2024
- Full Text
- View/download PDF
3. A patient with widespread firm nontender nodules
- Author
-
William A. Wright, MBChB, Jon Salisbury, MD, David Wright, MBChB, Tom Rider, BMBS, Timothy Corbett, PhD, Victoria Potter, MBBS, Pramila Krishnamurthy, PhD, and Tanya Basu, PhD
- Subjects
blastic plasmacytoid dendritic cell neoplasm ,CMML ,hematodermatology ,HSCT ,immunohistochemistry ,leukaemia cutis ,Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
4. P1288: UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME
- Author
-
Fabio Serpenti, Daniele Avenoso, Kenyon Michelle, Pramila Krishnamurthy, Varun Mehra, Austin Kulasekararaj, Shreyans Gandhi, Francesco Dazzi, Shah Mili Naresh, Ye Ting Leung, Sandra Anteh, Madson Correia de Farias, Styliani Bouziana, Christianne Bourlon, Oana Diana Dragoi, Tony Pagliuca, and Victoria Potter
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
5. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
- Author
-
Kavita Raj, Dirk-Jan Eikema, Vipul Sheth, Linda Koster, Liesbeth C. de Wreede, Didier Blaise, Carmela Di Grazia, Yener Koc, Victoria Potter, Patrice Chevallier, Lucia Lopez- Corral, Depei Wu, Stephan Mielke, Johan Maertens, Ellen Meijer, Anne Huynh, Jakob Passweg, Thomas Luft, Jose Antonio Pérez-Simón, Fabio Ciceri, Agnieszka Piekarska, G. Hayri Ozsan, Nicolaus Kröger, Marie Robin, and Ibrahim Yakoub-Agha
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p
- Published
- 2022
- Full Text
- View/download PDF
6. FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.
- Author
-
Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, and Victoria Potter
- Subjects
Allogeneic hematopoietic cell transplantation ,Lymphoma ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: The second decade of this millennium was characterized by a widespread availability of chimeric antigen receptor T-cell (CAR-T)therapies to treat relapsed and refractory lymphomas. As expected, the role and indication of allogeneic haematopoietic stem cell transplant(allo-HSCT)in the management of lymphoma changed. Currently a not unneglectable proportion of patients will be considered candidate for an allo-HSCT and the debate of which transplant platform should be offered is still active. Objectives:to report the outcome of patients affected with relapsed/refractory lymphoma and transplanted following reduced intensity conditioning at King’s College Hospital, London, between January 2009 and April2021. Methods: Conditioning was with fludarabine 150mg/m2 and melphalan 140mg/m2. The graft was unmanipulated G-CSF mobilized peripheral blood haematopoietic stem cells(PBSC). Graft-versus-host disease (GVHD) prophylaxis consisted of pre-transplant Campath at the total dose of 60 mg in unrelated donors and 30 mg in fully matched sibling donors, and ciclosporin. Results: One year and five years OS were87% and79.9%, respectively and median OS was not reached. Cumulative incidence of relapse was 16%.Incidence of acute GVHD was 48%(only grade I/II); no cases of grade III/IV were diagnosed. Chronic GVHD occurred in 39% of patients. TRM was 12%, with no cases developed within day 100 and 18months after the procedure. Conclusions:The outcomes of heavily pretreated lymphoma patients are favorable with median OS and survival not reached after a median of 49months. In conclusion, even if some lymphoma subgroups can’t be treated (yet) with advanced cellular therapies, this study confirms the role of allo-HSCT as a safe and curative strategy.
- Published
- 2023
- Full Text
- View/download PDF
7. Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
- Author
-
Daniele Avenoso, Dragana Milojkovic, James Clark, Christopher Pocock, Victoria Potter, Deborah Yallop, and Guy Hannah
- Subjects
CML ,COVID‐19 ,sudden blast crisis ,TRF ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract During the COVID‐19 pandemic, access to health services has been considerably restricted and furthermore, patients have been reluctant to attend for routine monitoring, and this may have had a negative impact in the management of patients affected with haematological disorders. Sudden blast crisis in chronic myeloid leukaemia is categorized as a rapid onset of blastic phase, after a documented ‘optimal’ response to tyrosine kinase inhibitor (TKI) therapy and within 3 months of a normal complete blood count. Herein, we describe a case of patient who developed sudden blast crisis after TKI while in treatment‐free remission.
- Published
- 2022
- Full Text
- View/download PDF
8. Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
- Author
-
Vipul Sheth, Victoria Potter, Hugues de Lavallade, Shreyans Gandhi, Austin Kulasekararaj, Pramila Krishnamurthy, Varun Mehra, Francesco Dazzi, Ghulam Mufti, Antonio Pagliuca, Donal Mclornan, and Kavita Raj
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing the risk of graft-versus-host disease (GVHD) in the case of T cell lineage mixed chimerism (MC) post allogeneic transplant in hematological malignancies. Many patients, however, fail to receive timely pDLI and have dismal outcomes, which are not taken into consideration. We compared long-term outcomes of 106 patients having T cell MC after day 60 and undergoing allogeneic stem cell allograft for acute leukemia from an unrelated donor (UD), with 111 patients having complete chimerism (CC). Fifty-three (56%) patients received prophylactic pDLI. Thirty-six patients (67%) had a response (RR), 17 (33%) had no response (NR), and fifty-two (54%) did not receive any pDLI (ND). OS was better in MC group as compared to CC (54% vs 43%, p = 0.04), mainly due to reduction in NRM (14% vs 25%, p = 0.05), and all grade acute and chronic GVHD. Within the MC group, response to pDLI was the only significant factor predicting OS, DFS, and relapses with NR and ND having unfavorable outcomes as compared to RR (p = 0.001). T cell MC in patients undergoing UD allografts with alemtuzumab is no longer an adverse prognostic factor, as compared to patients having CC, after timely implementation of pDLI.
- Published
- 2021
- Full Text
- View/download PDF
9. Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
- Author
-
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, and Marie Robin
- Subjects
KIR ,KIR2DS1 ,KIR3DL1 ,hematopoietic stem cell transplantation ,donor selection ,unrelated donor ,Immunologic diseases. Allergy ,RC581-607 - Published
- 2021
- Full Text
- View/download PDF
10. SARS-CoV-2 infection in aplastic anemia
- Author
-
Daniele Avenoso, Judith C.W. Marsh, Victoria Potter, Antonio Pagliuca, Simon Slade, Fiona Dignan, Eleni Tholouli, Sajjan Mittal, Bernard Davis, Sudhir Tauro, Rachel Kesse-Adu, Morag Griffin, Elspeth Payne, Shreyans Gandhi, and Austin G. Kulasekararaj
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2021
- Full Text
- View/download PDF
11. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
- Author
-
Vipul Sharad Sheth, Victoria Potter, Shreyans A. Gandhi, Austin Gladston Kulasekararaj, Hugues de Lavallade, Petra Muus, Antonio Pagliuca, Carmel F.M. Rice, Varun Mehra, Francesco Grimaldi, Shafqat Inam, Linda D. Barber, Ghulam J. Mufti, and Judith C. Marsh
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe aplastic anemia (SAA) among older patients remains poor and associated with increased risk for graft-versus-host disease (GVHD). In this retrospective study of 65 consecutive patients with acquired SAA who were transplanted using fludarabine, low-dose cyclophosphamide, and alemtuzumab (FCC), outcomes of 27 patients aged at least 50 years were compared with those of 38 patients younger than 50 years. The median age of the older cohort was 61 years (range, 51-71 years); 21 (78%) patients were transplanted from unrelated donors (3 of 21 from HLA 9/10 mismatch donors) and 6 from matched sibling donors. One-year GVHD-free, relapse-free survival (GRFS) was comparable to that of patients younger than 50 years (84% vs 94%, respectively; P = .23). Both groups showed low rates of acute (5% vs 4%) and chronic (18% vs 14%) GVHD, with no cases of severe GVHD among matched donor transplants, and similar 1-year transplant-related mortality (14% vs 5.4%, older vs younger; P = .23). HSCT comorbidity index (HTC-CI) scores were similar between the groups, but overall survival with an HCT-CI of at least 3 was lower compared with a score less than 3 (76% vs 98%; P = .005). Median donor T-cell chimerism among older patients was 64% and 60% at 1 and 3 years, respectively, and was similar to that of younger patients. Increased B regulatory cells potentially contributed to low alloreactivity and mutual donor-recipient tolerance in older patients. Effect of comorbidities rather than age alone may be a more important determinant of suitability for FCC HSCT in older patients.
- Published
- 2019
- Full Text
- View/download PDF
12. Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
- Author
-
Mili Shah, Andrea Kuhnl, Gregory Shields, Malur Sudhanva, Victoria Metaxa, Shu Wong, Deborah Yallop, Piers Patten, Shafqat Inam, Catherine Hockings, Orla Stewart, Reuben Benjamin, Kirsty Cuthill, Antonio Pagliuca, Victoria Potter, and Robin Sanderson
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2021
- Full Text
- View/download PDF
13. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
- Author
-
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, and Marie Robin
- Subjects
KIR ,KIR2DS1 ,KIR3DL1 ,hematopoietic stem cell transplantation ,donor selection ,unrelated donor ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Several competing models have been developed to classify donors as KIR-advantageous or disadvantageous. Basically, these models differ by grouping donors based on distinct KIR–KIR–ligand combinations or by haplotype motif assignment. This study aimed to validate different models for unrelated donor selection for patients with Myelodysplatic Syndromes (MDS) or secondary Acute Myeloid Leukemia (sAML). In a joint retrospective study of the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) registry data from 1704 patients with secondary AML or MDS were analysed. The cohort consisted mainly of older patients (median age 61 years) with high risk disease who had received chemotherapy-based reduced intensity conditioning and anti-thymocyte globulin prior to allogeneic HCT from well-matched unrelated stem cell donors. The impact of the predictors on Overall Survival (OS) and relapse incidence was tested in Cox regression models adjusted for patient age, a modified disease risk index, performance status, donor age, HLA-match, sex-match, CMV-match, conditioning intensity, type of T-cell depletion and graft type. KIR genes were typed using high-resolution amplicon-based next generation sequencing. In univariable and multivariable analyses none of the models predicted OS and the risk of relapse consistently. Our results do not support the hypothesis that optimizing NK-mediated alloreactivity is possible by KIR-genotype informed selection of HLA-matched unrelated donors. However, in the context of allogeneic transplantation, NK-cell biology is complex and only partly understood. KIR-genes are highly diverse and current assignment of haplotype motifs based on the presence or absence of selected KIR genes is over-simplistic. As a consequence, further research is highly warranted and should integrate cutting edge knowledge on KIR genetics, and NK-cell biology into future studies focused on homogeneous groups of patients and treatment modalities.
- Published
- 2021
- Full Text
- View/download PDF
14. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag
- Author
-
Bruno Fattizzo, Austin G. Kulasekararaj, Anita Hill, Nana Benson-Quarm, Morag Griffin, Talha Munir, Louise Arnold, Kathryn Riley, Robin Ireland, Hugues De Lavallade, Victoria Potter, Dario Consonni, Peter Hillmen, Ghulam J. Mufti, Wilma Barcellini, and Judith C. W. Marsh
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2019
- Full Text
- View/download PDF
15. Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
- Author
-
Vipul Sheth, Vanessa Kennedy, Hugues de Lavallade, Donal Mclornan, Victoria Potter, Brian G. Engelhardt, Bipin Savani, Wichai Chinratanalab, Stacey Goodman, John Greer, Adetola Kassim, Sally York, Michelle Kenyon, Shreyans Gandhi, Austin Kulasekararaj, Judith Marsh, Ghulam Mufti, Antonio Pagliuca, Madan Jagasia, and Kavita Raj
- Subjects
antithymocyte globulin ,alemtuzumab ,allogeneic stem cell transplant ,acute myeloid leukemia ,absolute lymphocyte counts ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Dosing regimens for antithymocyte globulin (ATG) and anti-CD52 antibody (alemtuzumab) for graft vs. host disease prophylaxis (GVHD) are empiric or weight-based, and do not account for individual patient factors. Recently, it has been shown that recipient peripheral blood absolute lymphocyte count (ALC) on the day of ATG administration interacts with the dose of ATG administered to predict transplantation outcome. Similarly, we wanted to analyze if the recipient ALC interacts with alemtuzumab dosing to predict outcomes. We retrospectively compared 364 patients, 124 patients receiving ATG (anti-thymocyte globulin) for GVHD prophylaxis, and undergoing unrelated first allogeneic transplant for myeloid and lymphoid malignancies (group 1) to 240 patients receiving alemtuzumab (group 2), in similar time period. There was no difference in survival or acute and chronic GVHD between 60 and 100 mg of alemtuzumab dosing. Unlike ATG (where the pre-transplant recipient ALC interacted with ATG dose on day of its administration (day 1) to predict OS and DFS (p = 0.05), within alemtuzumab group, the recipient ALC on second day of alemtuzumab administration (day 2) and its interaction with alemtuzumab dose strongly predicted OS, DFS and relapse (p = 0.05, HR-1.81, 1.1–3.3; p = 0.002, HR-2.41, CI, 1.3–4.2; and p = 0.003, HR-2.78, CI, 1.4–5.2), respectively. ALC (day 2) of 0.08 × 109/lit or higher, had a specificity of 96% in predicting inferior DFS. Like ATG, there is definite but differential interaction between the recipient peripheral blood ALC and alemtuzumab dose to predict OS, DFS, and relapses.
- Published
- 2019
- Full Text
- View/download PDF
16. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
- Author
-
Mutlu Arat, Manos Nikolousis, Zübeyde Nur Özkurt, Peter Dreger, Ibrahim Yakoub-Agha, Tiarlan Sirait, Gwendolyn Van Gorkom, Wilfried Schroyens, Javier de la Serna, Emmanuel Gyan, Meral Beksac, Liesbeth C. de Wreede, Árpád Illés, Stefan Schönland, John A. Snowden, Claude-Eric Bulabois, Blandine Guffroy, Anna Waszczuk-Gajda, Herrad Baurmann, Matjaz Sever, Junfeng Wang, Grzegorz W. Basak, Patrick Hayden, Victoria Potter, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
medicine.medical_specialty ,business.operation ,RENAL-FAILURE ,Immunology ,Population ,MULTICENTER ,BORTEZOMIB ,Lower risk ,Biochemistry ,Autologous stem-cell transplantation ,INSUFFICIENCY ,Internal medicine ,MULTIPLE-MYELOMA ,Medicine ,education ,Biology ,Survival analysis ,Univariate analysis ,education.field_of_study ,LENALIDOMIDE ,Transplantation ,business.industry ,Physics ,Mallinckrodt ,Cell Biology ,Hematology ,Log-rank test ,Human medicine ,business ,SCT - Abstract
Introduction Multiple myeloma (MM) patients with renal impairment (RI), especially dialysis-dependent (DD) RI, have poorer outcomes than MM patients with normal renal function. Autologous stem cell transplantation (ASCT) is a treatment option, but there is concern at a perceived higher risk of complications which may be limiting consideration of the use of ASCT in this population. The evidence is inconsistent among studies and interpretation is complicated by heterogeneous datasets, some dating to before the availability of novel agents. Finally, the reversibility of RI following ASCT is an important prognostic factor for both survival and quality of life. Aim To evaluate the safety and efficacy of ASCT in MM patients with DD RI transplanted in EBMT centres between 1997 and 2017. Methods Baseline characteristics at diagnosis, patient treatment regimens and clinical outcomes were collected using standardised report forms. OS was defined as the period between the date of ASCT and the date of death or the date of last observation. PFS was defined as the period between the date of ASCT and date of progression/relapse or death of any causes or the date of the last observation. Cox proportional hazard regression analysis was applied to assess risk factors for progression and death. Survival curves were plotted by the Kaplan-Meier method and compared using log-rank test. P Results A total of 109,959 adult MM patients are registered in the EBMT database as having undergone ASCT between 1997 and 2017. We further analysed 118 DD MM patients who had a first ASCT during this period. The median (range) age was 57 (27-71) years. Seventy (59%) patients were males. Forty nine patients (49/94 patients, 52%) had Karnofsky score ≥90. One hundred and ten patients were treated with hemodialysis and eight with peritoneal dialysis. A total of 68 (58%) patients had Light Chain MM, 43 kappa and 25 Lambda. In first-line induction therapy, 47/76 (62%) patients received bortezomib-based regimens. Forty-four (37%) patients achieved at least VGPR pre-ASCT. The median time from diagnosis to ASCT was 0.7 years (0.3-4.9). Melphalan doses were as follows: 140 mg/m2 (n=55, 67%), 70-100 mg/m2 (n=15, 18%), and >140 mg/m2 (n=12, 15%). The times to Neutrophil (>0.5) and Platelet (>20) engraftment were 12 (10-37) and 14 (4-128) days, respectively. The 30-day and 100-day transplant-related mortality (TRM) rates were 0.0% and 0.9%, respectively. ASCT was associated with a significant deepening of response (at least VGPR pre- vs post-ASCT: 36/93 (39%) vs 48/93 (52%), p < 0.001). The median PFS was 37 months (95% CI: 24-43) and 5-year PFS was 31% (95% CI: 20-41). The median OS was 102 months (95% CI: 67-129). Five-year OS post-ASCT was 62% (52-72) and 10-year OS 36% (17-55). Thirty-one (26%) DD MM patients achieved dialysis independence. There were no differences in PFS or OS when comparing the 1997-2007 and 2008-2017 cohorts: 5-year PFS - 28% (6-49) vs 31% (19-43) (p=0.7) and 5-year OS - 61% (38-84) vs 63% (51-74) (p=0.9), respectively. On univariate analysis of factors affecting PFS, achievement of an Overall Response Rate (ORR) (CR+VGPR+PR vs. Other) pre-ASCT was associated with a lower risk (HR 0.467, p=0.032) and older age (>55 years) with a higher risk (HR 1.786, p=0.035) of post-ASCT progression. Age higher than 55 (HR 2.033, 95%CI: 0.992 - 4.166, p=0.053) increased and achievement of at least VGPR pre-transplant (HR 0.494, 95%CI: 0.224 - 1.091, p=0.081, on the verge of statistical significance) decreased the risk of death. Conclusion To the best of our knowledge, the DIADEM study is the largest analysis of ASCT in DD MM pts to date. This cohort of 118 unselected patients had an OS comparable to patients without RI. This may reflect patient selection based on younger age, Karnofsky scores and pre-ASCT response. The low TRM and excellent outcomes support consideration of the use of ASCT in pts with DD RI. Notably, more than a quarter of patients became dialysis independent, an outcome likely to confer an improved Quality-of-Life.. These results can also inform the debate around the role of renal transplantation in younger DD MM patients who do not achieve dialysis independence. Disclosures Snowden: IDMC: Honoraria; Kiadis: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Mallinckrodt: Honoraria; Jazz: Honoraria; Gilead: Honoraria. Dreger:MSD: Membership on an entity's Board of Directors or advisory committees, Other: Sponsoring of Symposia; AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche: Consultancy; AbbVie, Gilead, Novartis, Riemser, Roche: Speakers Bureau; Neovii, Riemser: Research Funding. Illés:Takeda, Seattle: Research Funding; Janssen, Celgene, Novartis, Takeda, Roche, Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees. Basak:Teva: Honoraria; Celgene: Honoraria. Gyan:Pfizer: Honoraria. Hayden:Alnylam: Honoraria; Amgen: Honoraria. Beksac:Amgen: Consultancy; Celgene: Consultancy; Janssen&Janssen: Consultancy; Takeda: Consultancy. Schönland:Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Medac: Other: Travel Grant; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Prothena: Membership on an entity's Board of Directors or advisory committees, Research Funding.
- Published
- 2023
17. A patient with widespread firm non-tender nodules
- Author
-
William A. Wright, Jon Salisbury, David Wright, Tom Rider, Timothy Corbett, Victoria Potter, Pramila Krishnamurthy, and Tanya Basu
- Subjects
Dermatology - Published
- 2023
18. Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
- Author
-
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Maria Wagner, Jurjen Versluis, Thomas Schroeder, Igor Wolfgang Blau, Gerald Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kröger, Victoria Potter, Edouard Forcade, Jakob Passweg, Régis Peffault de Latour, Johan Maertens, Keith Wilson, Jean-Henri Bourhis, Bipin Savani, Fabio Ciceri, Arnon Nagler, and Mohamad Mohty
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
19. Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys
- Author
-
Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Victoria Potter, Ibrahim Yakoub-Agha, Nathalie Fegueux, Michael Daskalakis, Matthew P. Collin, Peter Dreger, Nicolaus Kröger, Urs Schanz, Adrian Bloor, Arnold Ganser, Caroline Besley, Gerald Wulf, Urban Novak, Ivan Moiseev, Helene Schoemans, Grzegorz W Basak, Christian Chabannon, Anna Sureda, Bertram Glass, and Zinaida Peric
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
20. Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme
- Author
-
Henry Wood, Christianne Bourlon, Austin Kulasekararaj, Albert Borg, Jiri Pavlu, Patrick Elder, David C Taussig, Scott Veitch, Steven Knapper, Jad Othman, Richard Dillon, James Aries, Emily Mitchell, Faisal Basheer, Steven Leak, Vidhya Murthy, Joe W Cross, Priyanka Mehta, Manish Jain, Anjum Khan, Ho Lam, Sarah Leong, Jenny O'Nions, Charles Craddock, Victoria Potter, Mhairi Copland, and Pramila Krishnamurthy
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
21. Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?
- Author
-
Stephen Boyle, Robin Sanderson, Maeve A. O'Reilly, Tobias F. Menne, Jane Norman, Adrian Bloor, Sanne Lugthart, Sridhar Chaganti, Carlos Gonzalez-Arias, Ceri Jones, Anne-Louise Latif, Reuben Benjamin, Piers Patten, Deborah Yallop, Victoria Potter, Claire Roddie, and Andrea Kuhnl
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
22. Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes
- Author
-
Ruta Maniusyte, Angharad Pryce, Rachel Pearce, John A Snowden, Ram Malladi, Victoria Potter, Julia Lee, Marie Wilson, Antonio Pagliuca, Eduardo Olavarria, Renuka Palanicawandar, Chloe Anthias, Rachel Pawson, and Robert David Danby
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
23. Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
- Author
-
Marie Robin, Luuk Gras, Linda Koster, Riccardo Saccardi, Jürgen Finke, Edouard Forcade, Montserrat Rovira, Guido Kobbe, Péter Reményi, Jane Apperley, Arghirescu Smaranda, Jacques-Olivier Bay, Jochen Casper, Liesbeth C. de Wreede, Sebastian Giebel, Giovanni Grillo, Inmaculada Heras, Victoria Potter, Johanna Tischer, Ilze Trociukas, David Nachbaur, Joanna Drozd-Sokolowska, Kavita Raj, Carmelo Gurnari, Ibrahim Yakoub-Agha, Francesco Onida, Christof Scheid, and Donal McLornan
- Subjects
Transplantation ,Hematology - Published
- 2023
24. Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS
- Author
-
Justin Loke, Nicholas McCarthy, Aimee E Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles R Crawley, Maria Gilleece, Andrew J Peniket, Rachel Protheroe, Rahuman Salim, Eleni Tholouli, Keith WIlson, Georgia Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, and Sylvie D Freeman
- Subjects
Hematology - Abstract
Allogeneic stem-cell transplantation allows the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report the prognostic impact of these biomarkers in patients allografted for AML/MDS. 187 patients from FIGARO, a randomized trial of reduced-intensity conditioning regimens in AML/MDS, were alive and relapse-free, at the first MRD timepoint and provided bone marrow for flow cytometric MRD monitoring and blood samples for T-cell chimerism analysis, requested to month+12. 29 (15.5%) patients had at least one MRD-positive result post-transplant. MRD-positivity was associated with reduced overall survival (OS) (HR:2.18, p=0.0028) as a time-varying Cox variable and remained significant irrespective of pre-transplant MRD status in multivariate analyses (p
- Published
- 2023
25. Data from Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
- Author
-
Mohamad Mohty, Arnon Nagler, Bipin N. Savani, Jordi Esteve, Gesine Bug, Alexandros Spyridonidis, Iman Abou Dalle, Fabio Ciceri, Jaime Sanz, Didier Blaise, Gerard Socié, Riitta Niittyvuopio, Victoria Potter, Igor Wolfgang Blau, Dietrich Beelen, Myriam Labopin, Christoph Schmid, and Ali Bazarbachi
- Abstract
Purpose:Relapsed acute myeloid leukemia (AML) post allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis.Experimental Design:To assess prognosis of patients with recurrent AML post allo-HCT over time, we analyzed European Society for Blood and Marrow Transplantation registry data of 8,162 adult patients with AML who relapsed between 2000 and 2018 after allo-HCT performed in first complete remission from matched sibling, unrelated, or haploidentical donors.Results:The 2-year overall survival (OS) rate from relapse was 17%. For 3,630 patients, P = 0.001). Improvement over time was noted both after relapse within and beyond 6 months from allo-HCT. On multivariate analysis among patients P < 0.02 for 2010–2014 and HR, 0.72; P = 0.0002 for 2015–2018), good performance status, favorable cytogenetics, and longer time from transplant to relapse, but negatively affected by increasing age. In contrast, among 4,532 patients, >50 years of age, the year of relapse had no influence on OS (16% for 2000–2004 and 14% for 2015–2018; P = 0.56). Regarding treatment, encouraging results were observed after second allo-HCT, which was performed within 2 years after relapse in 17% of the entire cohort, resulting in a 2-year OS of 30.7%.Conclusions:Outcome after posttransplant relapse among younger patients has improved significantly in recent years, likely reflecting, among other factors, the efficacy of posttransplant salvage including second allo-HCT.
- Published
- 2023
26. Supplementary Data from Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
- Author
-
Mohamad Mohty, Arnon Nagler, Bipin N. Savani, Jordi Esteve, Gesine Bug, Alexandros Spyridonidis, Iman Abou Dalle, Fabio Ciceri, Jaime Sanz, Didier Blaise, Gerard Socié, Riitta Niittyvuopio, Victoria Potter, Igor Wolfgang Blau, Dietrich Beelen, Myriam Labopin, Christoph Schmid, and Ali Bazarbachi
- Abstract
Supplementary tables
- Published
- 2023
27. Validation of the Transplant Conditioning Intensity (TCI) Index for Allogeneic Hematopoietic Cell Transplantation
- Author
-
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Wagner-Drouet, Jurjen Versluis, thomas schroeder, Igor-Wolfgang Blau, Gerald Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kroeger, Victoria Potter, Edouard Forcade, Jakob Passweg, Regis Peffault de Latour, Johan Maertens, Keith Wilson, Jean Henri Bourhis, Jürgen Finke, Eolia Brissot, Ali Bazarbachi, Sebastian Giebel, Bipin N. Savani, Arnon Nagler, Fabio Ciceri, and Mohamad Mohty
- Abstract
The intensity of the conditioning regimen given before allogeneic hematopoietic cell transplantation (allo-HCT) can vary substantially. To confirm the ability of the recently developed transplant conditioning intensity (TCI) score to stratify the preparative regimens of allo-HCT, we used an independent and contemporary patient cohort of 4060 transplant recipients with acute myeloid leukemia meeting inclusion criteria from the discovery study (allo-HCT in first complete remission, matched donor), but who were allografted in a more recent period (2018–2021) and were one decade older (55–75 years, median 63.4 years), we assigned them to a TCI category (low n = 1934, 48%; intermediate n = 1948, 48%, high n = 178, 4%) according to the calculated TCI score ([1–2], [2.5–3.5], [4–6], respectively), and examined the validity of the TCI category in predicting early non-relapse mortality (NRM), 2-year NRM and relapse (REL). In the unadjusted comparison, the TCI index provided a highly significant risk stratification for d100 and d180 NRM, NRM and REL risk. In the multivariate analysis adjusted for significant variables, there was an independent strong association of TCI with early NRM, NRM and REL. In summary, we confirm in contemporary treated patients that TCI reflects the conditioning regimen related morbidity and anti-leukemic efficacy highly satisfactorily and across other established prognostic factors. TCI has all the features to be used as a well-defined, easy calculated and reproducible tool to define and measure intensity of the preparative regimen.
- Published
- 2023
28. Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
- Author
-
Victoria Potter, Luuk Gras, Anja van Biezen, Nicolaus Kroeger, Katja Sockel, Arnold Ganser, Jürgen Finke, helene labussiere, Regis Peffault de Latour, Yener Koc, Lone Friis, Urpu Salmenniemi, Pavel Jindra, Thomas Schroeder, Johanna Tischer, Mutlu Arat, María Pascual, Liesbeth de Wreede, Patrick Hayden, Kavita Raj, Joanna Drozd-solowska, Christof Scheid, Donal McLornan, Marie Robin, and Ibrahim Yakoub-Agha
- Abstract
The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential(Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative(MAC) and reduced intensity conditioning(RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC(n=158,) Seq(n=105,), and MAC(n=40, ). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years(IQR 53.5 - 65.6). For the entire cohort, 3yr overall survival(OS) was 50%(95% CI45-56%) and relapse free survival(RFS) 45%(95%CI 40-51%). No differences in outcomes were observed per protocol with respect to OS and RFS. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and >20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status.
- Published
- 2023
29. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation : A study on behalf of the Acute Leukemia Working Party of the EBMT
- Author
-
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kröger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, and Mohamad Mohty
- Subjects
Transplantation ,Medizin ,Hematology - Abstract
Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.
- Published
- 2023
30. Systematic screening and focused evaluation for veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) following allogeneic stem cell transplant is associated with earlier diagnosis and prompt institution of defibrotide treatment
- Author
-
Daniele Avenoso, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Austin Kulasekararaj, Shreyans Gandhi, Francesco Dazzi, Mili Naresh Shah, Henry Wood, Ye Ting Leung, Alicia Eaton, Sandra Anteh, Maria Cuadrado, Madson Correia de Farias, Christienne Bourlon, Diana Oana Dragoi, Prudence Hardefeldt, Antonio Pagliuca, and Victoria Potter
- Abstract
Sinusoidal obstructive syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication following haemopoietic stem cell transplantation (HSCT). The availability of new drugs for malignant hematological conditions has allowed more patients to be eligible for allogeneic haematopoietic stem cell transplants, which has translated into a significant proportion of transplant patients having multiple risk factors for VOD/SOS. Based on these considerations, we undertook a dedicated weekly VOD/SOS ward round, aiming to facilitate early diagnosis of VOD/SOS and pre-emptively identify patients at risk, where a careful evaluation of differential diagnosis is essential. Herein, we present the results of our VOD/SOS ward round; between September 2020 and April 2022, 110 consecutive patients were evaluated in a focused VOD/SOS ward round. From the 110 patients, 108 had undergone HSCT and had at least one known risk factor for developing VOD/SOS. The median number of risk factors present in the VOD/SOS group and non-VOD/SOS group was five (range: three to six) and three (range: zero to seven), respectively. Late-onset VOD/SOS was diagnosed in 45% of our patients. The early identification of patients with multiple risk factors for VOD/SOS allowed an earlier diagnosis and the administration of defibrotide on the same day of diagnosis, which was two days earlier than our previous experience prior to the implementation of this protocol.
- Published
- 2022
31. Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London
- Author
-
Richard Sullivan, Saoirse Dolly, Gincy George, Piers E.M. Patten, Kieran Palmer, Elinor J. Sawyer, Andrea D'Souza, James Spicer, Simon Gomberg, Reuben Benjamin, Paul Ross, Kamarul Zaki, Anna Haire, Ailsa Sita-Lumsden, Austin G. Kulasekararaj, Sophie Papa, Fidelma Cahill, Muhammed Mansour Ceesay, Victoria Potter, Sheeba Irshad, Thinzar Ko Ko, Mieke Van Hemelrijck, Beth Russell, Debra H. Josephs, Claire N. Harrison, Paul Fields, Danielle Crawley, Antonio Pagliuca, Vallari Shah, Deborah Enting, Rushan Sylva, Angela Swampillai, Harriet Wylie, Charlotte Moss, Anne Rigg, David Wrench, Shahram Kordasti, and Maria J. Monroy-Iglesias
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Patient characteristics ,Article ,Internal medicine ,Neoplasms ,Cox proportional hazards regression ,Cancer centre ,London ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,SARS-CoV-2 ,Cancer ,COVID-19 ,Translational research ,Middle Aged ,medicine.disease ,Hospitals ,Risk factors ,Oncology ,Raised CRP ,Hematologic Neoplasms ,Haematological cancer ,Female ,business - Abstract
Background Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death. Methods Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy’s Cancer Centre and King’s College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality. Results Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died 2–5 years [2.81 (1.41–5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients ( Conclusions Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients.
- Published
- 2021
32. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
- Author
-
Marie Robin, Liesbeth C. de Wreede, Eric Padron, Katerina Bakunina, Pierre Fenaux, Linda Koster, Aziz Nazha, Dietrich W. Beelen, Raajit K. Rampal, Katja Sockel, Rami S. Komrokji, Nico Gagelmann, Dirk-Jan Eikema, Aleksandar Radujkovic, Jürgen Finke, Victoria Potter, Sally B. Killick, Faezeh Legrand, Eric Solary, Angus Broom, Guillermo Garcia-Manero, Vittorio Rizzoli, Patrick Hayden, Mrinal M. Patnaik, Francesco Onida, Ibrahim Yakoub-Agha, and Raphael Itzykson
- Subjects
Adult ,Male ,Adolescent ,Immunology ,Hematopoietic Stem Cell Transplantation ,Leukemia, Myelomonocytic, Chronic ,Cell Biology ,Hematology ,Middle Aged ,Biochemistry ,Young Adult ,Leukemia, Myelomonocytic, Juvenile ,Humans ,Transplantation, Homologous ,Aged ,Retrospective Studies - Abstract
To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of CMML patients 18-70 years old diagnosed between 2000 and 2014 from an international CMML dataset (n = 730) and the EBMT registry (n = 384). The prognostic impact of allo-HCT was analyzed through univariable and multivariable time-dependent models and with a multistate model, accounting for age, sex, CMML prognostic scoring system (low or intermediate-1 grouped as lower-risk, intermediate-2 or high as higher-risk) at diagnosis, and AML transformation. In univariable analysis, lower-risk CMMLs had a 5-year overall survival (OS) of 20% with allo-HCT vs 42% without allo-HCT (P < .001). In higher-risk patients, 5-year OS was 27% with allo-HCT vs 15% without allo-HCT (P = .13). With multistate models, performing allo-HCT before AML transformation reduced OS in patients with lower-risk CMML, and a survival benefit was predicted for men with higher-risk CMML. In a multivariable analysis of lower-risk patients, performing allo-HCT before transformation to AML significantly increased the risk of death within 2 years of transplantation (hazard ratio [HR], 3.19; P < .001), with no significant change in long-term survival beyond this time point (HR, 0.98; P = .92). In higher-risk patients, allo-HCT significantly increased the risk of death in the first 2 years after transplant (HR 1.46; P = .01) but not beyond (HR, 0.60; P = .09). Performing allo-HCT before AML transformation decreases life expectancy in lower-risk patients but may be considered in higher-risk patients.
- Published
- 2022
33. Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
- Author
-
Victoria Potter, Daniele Avenoso, Dragana Milojkovic, Guy Hannah, James Clark, Christopher Pocock, and Deborah Yallop
- Subjects
Blast Crisis ,Coronavirus disease 2019 (COVID-19) ,business.industry ,medicine.drug_class ,Pandemic ,Cancer research ,Medicine ,business ,Chronic myeloid leukaemia ,Prolonged treatment ,De-escalation ,Tyrosine-kinase inhibitor - Published
- 2021
34. Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Arnon Nagler, Myriam Labopin, Alexander D. Kulagin, Andrea Velardi, Jaime Sanz, Hélène Labussière-Wallet, Victoria Potter, Jurgen Kuball, Simona Sica, Elena N. Parovichnikova, Wolfgang Bethge, Xavier Leleu, Uwe Platzbecker, Friedrich Stölzel, Fabio Ciceri, and Mohamad Mohty
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
35. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
- Author
-
Christian Koenecke, Dirk-Jan Eikema, Sheree Hazelaar, Thomas Schroeder, Victoria Potter, Nicolaus Kröger, Martin Bornhäuser, Jürgen Finke, Uwe Platzbecker, Aleksandar Radujkovic, Arnold Ganser, Urpu Salmenniem, Didier Blaise, Guido Kobbe, Ellen Meijer, Lone Friis, Johan Maertens, Dolores Caballero, Jan J. Cornelissen, Attilio Olivieri, Ozet Gulsum, Patrick J. Hayden, Francesco Onida, Marie Robin, Ibrahim Yakoub-Agha, Hematology, and CCA - Imaging and biomarkers
- Subjects
Transplantation ,Science & Technology ,CLINICAL-FEATURES ,Immunology ,Medizin ,Hematopoietic Stem Cell Transplantation ,Biophysics ,CHRONIC MYELOMONOCYTIC LEUKEMIA ,Graft vs Host Disease ,Hematology ,Prognosis ,Oncology ,Neoplasms ,Cytogenetic Analysis ,Humans ,Life Sciences & Biomedicine ,Retrospective Studies - Abstract
ispartof: BONE MARROW TRANSPLANTATION vol:57 issue:10 pages:1607-1611 ispartof: location:England status: published
- Published
- 2022
36. Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper
- Author
-
Mike Dennis, Mhairi Copland, Harpreet Kaur, Jonathan Kell, Emmanouil Nikolousis, Priyanka Mehta, Renuka Palanicawandar, Victoria Potter, Kavita Raj, Ian Thomas, and Andrew Wilson
- Subjects
Leukemia, Myeloid, Acute ,Frailty ,Remission Induction ,Humans ,Hematology - Abstract
No abstract available.
- Published
- 2022
37. SARS-CoV-2 infection in aplastic anemia
- Author
-
Austin G. Kulasekararaj, Antonio Pagliuca, Bernard A. Davis, Judith C. W. Marsh, Victoria Potter, Sudhir Tauro, Eleni Tholouli, Morag Griffin, Fiona L Dignan, Rachel Kesse-Adu, Simon Slade, Daniele Avenoso, Sajjan Mittal, Elspeth Payne, and Shreyans Gandhi
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Anemia, Aplastic ,COVID-19 ,Humans ,Medicine ,Hematology ,business ,Virology - Published
- 2021
38. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma
- Author
-
Jakob Passweg, Gwendolyn Van Gorkom, Dietrich W. Beelen, Emmanuel Gyan, Patrick Hayden, Fabrizio Carnevale Schianca, Jean Bourhis, Stephen P. Robinson, Federica Sorà, Corentin Orvain, Victoria Potter, Peter Dreger, Leopold Sellner, Nicolaus Kröger, Gerald Wulf, Elisabeth Vandenberghe, Ibrahim Yakoub-Agha, Goda Choi, Johannes Schetelig, Linda Koster, Jiri Mayer, Francesco Zallio, Didier Blaise, Urs Schanz, Pavel Jindra, Silvia Montoto, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
Oncology ,medicine.medical_specialty ,Follicular lymphoma ,MEDLINE ,Medizin ,INHIBITION ,Cancer immunotherapy ,03 medical and health sciences ,0302 clinical medicine ,Targeted therapies ,Clinical trials ,Internal medicine ,Correspondence ,medicine ,Humans ,In patient ,RITUXIMAB ,Lymphoma, Follicular ,ComputingMilieux_MISCELLANEOUS ,Quinazolinones ,Transplantation ,OUTCOMES ,business.industry ,Hematopoietic Stem Cell Transplantation ,Correction ,Hematology ,medicine.disease ,3. Good health ,Purines ,030220 oncology & carcinogenesis ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,TRIAL ,Stem cell ,business ,Idelalisib ,030215 immunology - Abstract
International audience
- Published
- 2020
39. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- Author
-
Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jozwik, Oana C Mirci-Danicar, Giovanna Lucchini, Danielle Pinner, Nitin Jain, Hagop Kantarjian, Nicolas Boissel, Marcela V Maus, Matthew J Frigault, André Baruchel, Mohamad Mohty, Athos Gianella-Borradori, Florence Binlich, Svetlana Balandraud, Fabien Vitry, Elisabeth Thomas, Anne Philippe, Sylvain Fouliard, Sandra Dupouy, Ibtissam Marchiq, Maria Almena-Carrasco, Nicolas Ferry, Sylvain Arnould, Cyril Konto, Paul Veys, Waseem Qasim, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kuhnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Oana Ciocarlie, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Kimberley Gilmour, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Marina Konopleva, William Wierda, Elias Jabbour, Partow Kebrieai, Emily Jones, Kara McGee, Marcela Maus, Matthew Frigault, Jami Brown, Vesselina Toncheva, Keagan Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews, Thomas Spitzer, Emmanuel Raffoux, Etienne Lengliné, Raphael Itzykson, Florence Rabian, Jérôme Larghero, Isabelle Madelaine, Elie Azoulay, Emmanuelle Clappier, Sophie Caillat-Zucman, Martine Meunier, Karine Celli-Lebras, Marie-Thérèse Tremorin, Karima Yakouben, Françoise Mechinaud-Heloury, Audrey Grain, Aurélia Alimi, Julie Roupret, Delphine Chaillou, Hélène Cavé, Aurelie Caye-Eude, Odile Fenneteau, Elodie Lainey, Jerome Naudin, Eolia Brissot, Remy Dulery, Florent Malard, Clémence Mediavilla, Agnès Bonnin, Anne Vekhoff, Tounes Ledraa, and Anne Daguenel-Nguyen
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Cyclophosphamide ,medicine.medical_treatment ,Antigens, CD19 ,030204 cardiovascular system & hematology ,Immunotherapy, Adoptive ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Adverse effect ,Gene Editing ,Cytopenia ,Receptors, Chimeric Antigen ,business.industry ,General Medicine ,Immunotherapy ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Fludarabine ,Cytokine release syndrome ,Child, Preschool ,Feasibility Studies ,Alemtuzumab ,Female ,Cytokine Release Syndrome ,business ,Progressive disease ,medicine.drug - Abstract
Summary Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is one such product investigated in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Two multicentre phase 1 studies aimed to investigate the feasibility, safety, and antileukaemic activity of UCART19 in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Methods We enrolled paediatric or adult patients in two ongoing, multicentre, phase 1 clinical trials to evaluate the safety and antileukaemic activity of UCART19. All patients underwent lymphodepletion with fludarabine and cyclophosphamide with or without alemtuzumab, then children received UCART19 at 1·1–2·3 × 106 cells per kg and adults received UCART19 doses of 6 × 106 cells, 6–8 × 107 cells, or 1·8–2·4 × 108 cells in a dose-escalation study. The primary outcome measure was adverse events in the period between first infusion and data cutoff. These studies were registered at ClinicalTrials.gov, NCT02808442 and NCT02746952. Findings Between June 3, 2016, and Oct 23, 2018, seven children and 14 adults were enrolled in the two studies and received UCART19. Cytokine release syndrome was the most common adverse event and was observed in 19 patients (91%); three (14%) had grade 3–4 cytokine release syndrome. Other adverse events were grade 1 or 2 neurotoxicity in eight patients (38%), grade 1 acute skin graft-versus-host disease in two patients (10%), and grade 4 prolonged cytopenia in six patients (32%). Two treatment-related deaths occurred; one caused by neutropenic sepsis in a patient with concurrent cytokine release syndrome and one from pulmonary haemorrhage in a patient with persistent cytopenia. 14 (67%) of 21 patients had a complete response or complete response with incomplete haematological recovery 28 days after infusion. Patients not receiving alemtuzumab (n=4) showed no UCART19 expansion or antileukaemic activity. The median duration of response was 4·1 months with ten (71%) of 14 responders proceeding to a subsequent allogeneic stem-cell transplant. Progression-free survival at 6 months was 27%, and overall survival was 55%. Interpretation These two studies show, for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive leukaemia. UCART19 exhibited in-vivo expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results this study are an encouraging step forward for the field of allogeneic CAR T cells, and UCART19 offers the opportunity to treat patients with rapidly progressive disease and where autologous CAR-T-cell therapy is unavailable. Funding Servier.
- Published
- 2020
40. Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
- Author
-
Arnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, Myriam Labopin, Nicolaus Kröger, Gerard Socié, Tobias Gedde-Dahl, Victoria Potter, Thomas Schroeder, Uwe Platzbecker, Arnold Ganser, Didier Blaise, Urpu Salmenniemi, Johan Maertens, Charles Craddock, Hélène Labussière-Wallet, Ibrahim Yakoub-Agha, Bipin Savani, and Mohamad Mohty
- Subjects
Transplantation ,Leukemia, Myeloid, Acute ,Transplantation Conditioning ,Recurrence ,Remission Induction ,Medizin ,Hematopoietic Stem Cell Transplantation ,Humans ,Graft vs Host Disease ,Neoplasms, Second Primary ,Hematology ,Middle Aged ,Retrospective Studies - Abstract
Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.
- Published
- 2022
41. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
- Author
-
Reuben Benjamin, Nitin Jain, Marcela V Maus, Nicolas Boissel, Charlotte Graham, Agnieszka Jozwik, Deborah Yallop, Marina Konopleva, Matthew J Frigault, Takanori Teshima, Koji Kato, Floriane Boucaud, Svetlana Balandraud, Athos Gianella-Borradori, Florence Binlich, Ibtissam Marchiq, Sandra Dupouy, Maria Almena-Carrasco, Matthieu Pannaux, Sylvain Fouliard, Eolia Brissot, Mohamad Mohty, Laarni Bonganay, Lorraine Catt, Jackie Chappell, Gary Cheung, Vicky Chu, Kirsty Cuthill, Steven Devereux, Alan Dunlop, Rose Ellard, Farzin Farzeneh, Najeem Folarin, Elka Giemza, Shireen Kassam, Majid Kazmi, Andrea Kuhnl, Jen Lewis, Maria Liskova, Alice Mason, Victoria Metaxa, Ghulam Mufti, Helena Munro, Antonio Pagliuca, Piers Patten, Victoria Potter, Carmel Rice, Adeel Saleem, Robin Sanderson, Orla Stewart, Elias Jabbour, Emily Jones, Hagop Kantarjian, Partow Kebriaei, Kara McGee, William Wierda, Jami Brown, Keagan Casey, Matthew Frigault, Hanno Hock, Richard Mathews, Marcela Maus, Meaghan A McKeown, Thomas Spitzer, Vesselina Toncheva, Elie Azoulay, Sophie Caillat-Zucman, Karine Celli-Lebras, Emmanuelle Clappier, Raphael Itzykson, Jérôme Larghero, Etienne Lengliné, Isabelle Madelaine, Martine Meunier, Florence Rabian, Emmanuel Raffoux, Marie-Thérèse Tremorin, Agnes Bonnin, Anne Daguenel-Nguyen, Remy Dulery, Tounes Ledraa, Florent Malard, Clemence Mediavilla, and Anne Vekhoff
- Subjects
Adult ,Male ,Receptors, Chimeric Antigen ,Antigens, CD19 ,Hematopoietic Stem Cell Transplantation ,Humans ,Female ,Hematology ,Neoplasm Recurrence, Local ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Cytokine Release Syndrome ,Lymphoma, Follicular - Abstract
The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic activity of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.This phase 1, open-label study was conducted at eight centres across France, the UK, the USA, and Japan. Adult patients aged 16-70 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukaemia who had morphological relapse or a minimal residual disease level of at least 1 × 10Between Aug 1, 2016, and June 30, 2020, 25 patients were enrolled in the study and treated with UCART19. Median duration of follow-up was 12·8 months (IQR 2·8-24·8). Median age was 37 years (IQR 28-45). 14 (56%) patients were male and 11 (44%) female. 17 (68%) patients were White, two (8%) Black, two (8%) Asian, and four (16%) from other racial or ethnic groups. Three patients developed dose-limiting toxicities (one at each dose level); one had grade 4 cytokine release syndrome and two had grade 4 prolonged cytopenias. Grade 3 or higher cytokine release syndrome was reported in six (24%) patients and grade 3 or higher neurological toxicity in one (4%) patient. Grade 3 or higher infections occurred in seven (28%) patients, and grade 4 prolonged cytopenia in four (16%) patients. Two (8%) patients developed grade 1 acute cutaneous graft-versus-host disease. 14 patients died, nine from progressive disease and five from infections or other complications, of which four were considered to be related to UCART19 or lymphodepletion, or both. After a median of follow-up of 12·8 months (IQR 2·8-24·8), overall response rate was 48% (95% CI 28-69; 12 of 25 patients), duration of response and median relapse-free survival were 7·4 months (95% CI 1·8 to not calculable), progression-free survival was 2·1 months (95% CI 1·2-2·8), and overall survival was 13·4 months (95% CI 4·8-23·0).UCART19 had a manageable safety profile, and showed evidence of antileukaemic activity in heavily pretreated adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. This study shows that allogeneic off-the-shelf CAR T cells can be used safely to treat patients with relapsed B-cell acute lymphoblastic leukaemia.Servier.
- Published
- 2022
42. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
- Author
-
Dawn Swan, Patrick J. Hayden, Dirk‐Jan Eikema, Linda Koster, Sandra Sauer, Didier Blaise, Emma Nicholson, Neil Rabin, Cyrille Touzeau, Jennifer Byrne, Anne Huynh, Jan J. Cornelissen, Victoria Potter, Edouard Forcade, Christopher Parrish, John Gribben, Marie‐Lorraine Chretien, Stephan Mielke, Tobias Gedde‐Dahl, Péter Reményi, Panagiotis Tsirigotis, Antoni Garcia Guiñón, Meral Beksac, Stefan Schönland, Ibrahim Yakoub‐Agha, and Hematology
- Subjects
Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Transplantation, Autologous ,Dexamethasone ,Bortezomib ,Survival Rate ,Treatment Outcome ,Bone Marrow ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Multiple Myeloma ,Retrospective Studies ,Stem Cell Transplantation - Abstract
Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival (OS) has improved in recent years due to increased use of autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed MM and the advent of novel agents, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. To assess trends in ASCT including patient selection, choice of induction regimen, depth of response and survival, we performed a retrospective analysis of all patients undergoing first ASCT for MM in European Society for Blood and Marrow Transplantation centres between 1995 and 2019. A total of 117 711 patients across 575 centres were included. The number of transplants performed increased sevenfold across the study period. The median age increased from 55 to 61 years, and the percentage of patients aged >65 years rose from 7% to 30%. Use of chemotherapy-based induction fell significantly, being largely replaced by bortezomib-based regimens. The two-year complete response rate increased from 22% to 42%. The five-year progression-free survival and OS rates increased from 28% to 31% and from 52% to 69%, respectively. Transplant mortality fell from 5.9% to 1.5%. Ongoing advances in MM treatment may challenge the future role of ASCT. However, at the current time, ASCT remains central to the MM treatment paradigm.
- Published
- 2021
43. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study
- Author
-
Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin J Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Martin Maiers, Stephen Spellman, Jane Apperley, Peter Bardy, Ghislaine Bernard, Yves Bertrand, Adrian Bloor, Chiara Bonini, Stephane Buhler, Laura Bungener, Helen Campbell, Kristina Carlson, Ben Carpenter, Anne Cesbron, Christian Chabannon, Yves Chalandon, Jeremy Chapman, Réda Chebel, Patrice Chevallier, Gerda Choi, Matt Collin, Jan J Cornelissen, Charles Crawley, Lloyd D'Orsogna, Jean-Hugues Dalle, Eric Deconinck, Muriel DeMatteis, Mary Diviney, Anne Dormoy, Katia Gagne, Brenda Gibson, Maria Gilleece, David Gottlieb, John Gribben, Tayfun Güngör, Mike Haagenson, Cathie Hart, Rhonda Holdsworth, Ian Humphreys, Yoshihisa Kodera, Mickey Koh, Hélène Labussière-Wallet, Arjan C Lankester, Neubery Lardy, Sarah Lawson, Xavier Leleu, Stephen MacKinnon, Ram Malladi, Steven GE Marsh, Murray Martin, Neema P Mayor, I Grant McQuaker, Ellen Meijer, Satoko Morishima, Emmanouil Nikolousis, Kim Orchard, Jacob Passweg, Amit Patel, Katherine Patrick, Béatrice Pedron, Andy Peniket, Julia Perry, Eefke Petersen, Victoria Potter, Mike Potter, Rachel Protheroe, Nicole Raus, Carmen Ruiz de Elvira, Nigel Russell, Nicholaas PM Schaap, Urs Schanz, Harry Schouten, Roderick Skinner, John Snowden, Eric Spierings, Colin Steward, Eleni Tholouli, Alycia Thornton, Marcel Tilanus, Arnold van de Meer, Hendrik Veelkens, Paul Veys, Narelle Watson, Lyanne Weston, Keith Wilson, Marie Wilson, Robert Wynn, József Zsiros, University of Washington [Seattle], Harvard University [Cambridge], Frederick National Laboratory for Cancer Research (FNLCR), Uppsala Universitet [Uppsala], PathWest Murdoch / Fiona Stanley Hospital [Perth, WA, Australia] (PMFSH), Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Medical College of Wisconsin [Milwaukee] (MCW), Memorial Sloane Kettering Cancer Center [New York], Royal Free Hospital [London, UK], Center for International Blood and Marrow Transplant Research [Minneapolis, MN, USA] (CIBMTR), Aichi Medical University School of Medicine [Nagakute, Aichi, Japan] (AMUSM), Leiden University Medical Centre [Leyde, Pays-Bas], Leiden University, Geneva University Hospital (HUG), International Histocompatibility Working Group in Hematopoietic Cell Transplantation: Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen Spellman, Jean Villard, Phil Stevenson, Jane Apperley, Peter Bardy, Ghislaine Bernard, Yves Bertrand, Adrian Bloor, Chiara Bonini, Stephane Buhler, Laura Bungener, Helen Campbell, Kristina Carlson, Ben Carpenter, Anne Cesbron, Christian Chabannon, Yves Chalandon, Jeremy Chapman, Réda Chebel, Patrice Chevallier, Gerda Choi, Matt Collin, Jan J Cornelissen, Charles Crawley, Lloyd D'Orsogna, Jean-Hugues Dalle, Eric Deconinck, Muriel DeMatteis, Mary Diviney, Anne Dormoy, Katia Gagne, Brenda Gibson, Maria Gilleece, David Gottlieb, John Gribben, Tayfun Güngör, Mike Haagenson, Cathie Hart, Rhonda Holdsworth, Ian Humphreys, Yoshihisa Kodera, Mickey Koh, Hélène Labussière-Wallet, Arjan C Lankester, Neubery Lardy, Sarah Lawson, Xavier Leleu, Stephen MacKinnon, Ram Malladi, Steven Ge Marsh, Murray Martin, Neema P Mayor, I Grant McQuaker, Ellen Meijer, Satoko Morishima, Emmanouil Nikolousis, Kim Orchard, Jacob Passweg, Amit Patel, Katherine Patrick, Béatrice Pedron, Andy Peniket, Julia Perry, Eefke Petersen, Victoria Potter, Mike Potter, Rachel Protheroe, Nicole Raus, Carmen Ruiz de Elvira, Nigel Russell, Nicholaas Pm Schaap, Urs Schanz, Harry Schouten, Roderick Skinner, John Snowden, Eric Spierings, Colin Steward, Eleni Tholouli, Alycia Thornton, Marcel Tilanus, Arnold van de Meer, Hendrik Veelkens, Paul Veys, Narelle Watson, Lyanne Weston, Keith Wilson, Marie Wilson, Robert Wynn, József Zsiros, Leiden University Medical Center (LUMC), GAGNE, Katia, CCA - Cancer Treatment and quality of life, AII - Inflammatory diseases, Hematology, CCA - Cancer biology and immunology, Petersdorf, E. W., Carrington, M., O'Huigin, C., Bengtsson, M., De Santis, D., Dubois, V., Gooley, T., Horowitz, M., Hsu, K., Madrigal, J. A., Maiers, M. J., Malkki, M., Mckallor, C., Morishima, Y., Oudshoorn, M., Spellman, S. R., Villard, J., Stevenson, P., Maiers, M., Spellman, S., Apperley, J., Bardy, P., Bernard, G., Bertrand, Y., Bloor, A., Bonini, C., Buhler, S., Bungener, L., Campbell, H., Carlson, K., Carpenter, B., Cesbron, A., Chabannon, C., Chalandon, Y., Chapman, J., Chebel, R., Chevallier, P., Choi, G., Collin, M., Cornelissen, J. J., Crawley, C., D'Orsogna, L., Dalle, J. -H., Deconinck, E., Dematteis, M., Diviney, M., Dormoy, A., Gagne, K., Gibson, B., Gilleece, M., Gottlieb, D., Gribben, J., Gungor, T., Haagenson, M., Hart, C., Holdsworth, R., Humphreys, I., Kodera, Y., Koh, M., Labussiere-Wallet, H., Lankester, A. C., Lardy, N., Lawson, S., Leleu, X., Mackinnon, S., Malladi, R., Marsh, S. G., Martin, M., Mayor, N. P., Mcquaker, I. G., Meijer, E., Morishima, S., Nikolousis, E., Orchard, K., Passweg, J., Patel, A., Patrick, K., Pedron, B., Peniket, A., Perry, J., Petersen, E., Potter, V., Potter, M., Protheroe, R., Raus, N., Ruiz de Elvira, C., Russell, N., Schaap, N. P., Schanz, U., Schouten, H., Skinner, R., Snowden, J., Spierings, E., Steward, C., Tholouli, E., Thornton, A., Tilanus, M., van de Meer, A., Veelkens, H., Veys, P., Watson, N., Weston, L., Wilson, K., Wilson, M., Wynn, R., Zsiros, J., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: DA TI Staf (9), University of Zurich, and Petersdorf, Effie W
- Subjects
Oncology ,Male ,Hematopoietic Stem Cell Transplantation/methods ,[SDV]Life Sciences [q-bio] ,2720 Hematology ,Graft vs Host Disease ,Histocompatibility Testing ,0302 clinical medicine ,Graft vs Host Disease/genetics ,immune system diseases ,unrelated donor ,Exons/genetics ,graft-versus-host disease ,Medicine ,ddc:616 ,Hematopoietic Stem Cell Transplantation ,Exons ,Hematology ,Middle Aged ,3. Good health ,[SDV] Life Sciences [q-bio] ,surgical procedures, operative ,030220 oncology & carcinogenesis ,Histocompatibility ,HLA-B Antigens/genetics ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,EXPRESSION ,Adult ,medicine.medical_specialty ,Adolescent ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,610 Medicine & health ,Human leukocyte antigen ,Lower risk ,Risk Assessment ,Article ,Graft vs Host Disease/genetics/immunology ,03 medical and health sciences ,Internal medicine ,Journal Article ,Humans ,Retrospective Studies ,RECEPTOR ,business.industry ,MORTALITY ,RECOGNITION ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Transplantation ,Graft-versus-host disease ,hematopoietic-cell transplantation ,SEQUENCE-DERIVED PEPTIDES ,10036 Medical Clinic ,HLA-B Antigens ,10032 Clinic for Oncology and Hematology ,Multivariate Analysis ,RESIDUES ,HLA-B leader ,business ,030215 immunology - Abstract
Background: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of HLA-B gives rise to leader peptides containing methionine (Met; M) or threonine (Thr; T), which differentially influence natural killer and T-cell alloresponses. The main aim of the study was to evaluate the role of the leader dimorphism in GVHD after HLA-B-mismatched unrelated HCT. Methods: We did a retrospective cohort study of 33 982 patients who received an unrelated HCT done in Australia, Europe, Japan, North America, and the UK between Jan 1, 1988, and Dec 31, 2016. Data were contributed by participants of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. All cases were included and there were no exclusion criteria. Multivariate regression models were used to assess risks associated with HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 mismatching. Among the 33 982 transplantations, the risks of GVHD associated with HLA-B M and T leaders were established in 17 100 (50·3%) HLA-matched and 1457 (4·3%) single HLA-B-mismatched transplantations using multivariate regression models. Leader frequencies were defined in 2 004 742 BeTheMatch US registry donors. Findings: Between Jan 20, 2017, and March 11, 2019, we assessed 33 982 HCTs using multivariate regression models for the role of HLA mismatching on outcome. Median follow-up was 1841 days (IQR 909–2963). Mortality and GVHD increased with increasing numbers of HLA mismatches. A single HLA-B mismatch increased grade 3–4 acute GVHD (odds ratio [OR] 1·89, 95% CI 1·53–2·33; p
- Published
- 2021
44. Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
- Author
-
Arnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, Myriam Labopin, Nicolaus Kröger, Gerard Socié, Tobias Gedde-Dahl, Victoria Potter, Thomas Schroeder, Uwe Platzbecker, Arnold Ganser, Didier Blaise, Urpu Salmenniemi, Johan Maertens, Charles Craddock, Hélène Labussière-Wallet, Ibrahim Yakoub-Agha, Bipin Savani, and Mohamad Mohty
- Subjects
Transplantation ,Medizin ,Hematology - Abstract
In the original version of this article, the given and family names of Jacques-Emmanuel Galimard were incorrectly structured. The original article has been corrected. in press
- Published
- 2022
45. EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR‐T
- Author
-
Wendy Osborne, Tobias Menne, Reuben Benjamin, Deborah Yallop, Nicola Mulholland, Victoria Potter, R. Sanderson, M. Cuadrado, Piers Em Patten, Andrea Kuhnl, and George Petrides
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,PET-CT ,biology ,business.industry ,Hematology ,General Medicine ,medicine.disease ,Outcome (game theory) ,CD19 ,Internal medicine ,biology.protein ,Medicine ,Car t cells ,business ,B-cell lymphoma - Published
- 2021
46. Human parainfluenza virus type 3 infections in a haemato-oncology unit: social distancing measures needed in outpatient clinics
- Author
-
Melvyn Smith, Austin G. Kulasekararaj, Daniele Avenoso, Pramila Krishnamurthy, Mark Zuckerman, Victoria Potter, V. Anton-Vazquez, A Pagliuca, and Varun Mehra
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Physical Distancing ,Asymptomatic ,Ambulatory Care Facilities ,Respirovirus Infections ,Internal medicine ,Lower respiratory tract infection ,Epidemiology ,Medicine ,Outpatient clinic ,Humans ,Phylogeny ,Retrospective Studies ,business.industry ,Transmission (medicine) ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Parainfluenza Virus 3, Human ,Human Parainfluenza Virus ,Infectious Diseases ,Respiratory virus ,medicine.symptom ,business - Abstract
Summary Background Human parainfluenza virus type 3 (HPIV3) infections are associated with high mortality in immunocompromised settings, especially in bone marrow transplant recipients. Asymptomatic infection and lack of effective antiviral treatment makes HPIV3 prevention and treatment a real challenge. Aim To retrospectively investigate the epidemiological characteristics, clinical characteristics and outcomes of 51 haematology patients with confirmed HPIV3 infections, detected between February and May 2019 in the haematology unit at King's College Hospital, London. Methods Between February and May 2019, HPIV3 RNA was detected in combined nose and throat swab samples collected from 51 symptomatic haematology patients, 41 of whom attended the haematology outpatient unit. Clinical data were reviewed retrospectively and a timeline of patients' appointments drawn up to investigate transmission. Sequencing analysis was performed on 14 stored samples. Findings Fifty-one patients were identified with HPIV3 infection. Mean age was 54 years (SD: 12; range: 19–72) and 60% (31/51) were male. There were 41 (80%) bone marrow transplant recipients, 24 had an allograft, and 17 an autograft. Thirty-day and 3-month mortality post HPIV3 was 6% and 14%, respectively. Lower respiratory tract infection and inpatient acquisition were associated with higher mortality (6/7 vs 1/7, P = 0.010; and 5/7 vs 2/7, P = 0.031). Onset of HPIV3 infection in patients within 6 days of attending the clinic was associated with the clusters identified in phylogenetic analysis (64% (9/14) vs 21% (8/37); odds ratio: 6.5 (confidence interval: 95% 1.7–25); P = 0.006). Conclusion Timelines suggested community transmission, but also possible transmission patterns within the outpatients and subsequent nosocomial transmission within the same ward. Early recognition of HPIV3 infection and the use of polymerase chain reaction and sequence analysis is fundamental in identifying respiratory virus outbreaks and person-to-person transmission. Careful planning of outpatient clinic attendance is required to minimize contact and prevent respiratory virus transmission in immunosuppressed patients.
- Published
- 2021
47. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
- Author
-
Francesco Grimaldi, Varun Mehra, Carmel Rice, Judith C. W. Marsh, Vipul Sharad Sheth, Victoria Potter, Linda Barber, Ghulam J. Mufti, Shreyans Gandhi, Antonio Pagliuca, Hugues de Lavallade, Shafqat Inam, Austin G. Kulasekararaj, Petra Muus, Sheth, V. S., Potter, V., Gandhi, S. A., Kulasekararaj, A. G., de Lavallade, H., Muus, P., Pagliuca, A., Rice, C. F. M., Mehra, V., Grimaldi, F., Inam, S., Barber, L. D., Mufti, G. J., and Marsh, J. C.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Anemia ,Aplastic Anemia, FCC, Immunesuppression ,Graft vs Host Disease ,Comorbidity ,Antineoplastic Agents, Immunological ,Immune Reconstitution ,Internal medicine ,medicine ,Humans ,Alemtuzumab ,Aged ,Transplantation Chimera ,Transplantation ,business.industry ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Anemia, Aplastic ,Neoplasms, Second Primary ,Retrospective cohort study ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,United Kingdom ,Fludarabine ,Treatment Outcome ,surgical procedures, operative ,Graft-versus-host disease ,Cohort ,Female ,business ,medicine.drug - Abstract
Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe aplastic anemia (SAA) among older patients remains poor and associated with increased risk for graft-versus-host disease (GVHD). In this retrospective study of 65 consecutive patients with acquired SAA who were transplanted using fludarabine, low-dose cyclophosphamide, and alemtuzumab (FCC), outcomes of 27 patients aged at least 50 years were compared with those of 38 patients younger than 50 years. The median age of the older cohort was 61 years (range, 51-71 years); 21 (78%) patients were transplanted from unrelated donors (3 of 21 from HLA 9/10 mismatch donors) and 6 from matched sibling donors. One-year GVHD-free, relapse-free survival (GRFS) was comparable to that of patients younger than 50 years (84% vs 94%, respectively; P 5 .23). Both groups showed low rates of acute (5% vs 4%) and chronic (18% vs 14%) GVHD, with no cases of severe GVHD among matched donor transplants, and similar 1-year transplant-related mortality (14% vs 5.4%, older vs younger; P 5 .23). HSCT comorbidity index (HTC-CI) scores were similar between the groups, but overall survival with an HCT-CI of at least 3 was lower compared with a score less than 3 (76% vs 98%; P 5 .005). Median donor T-cell chimerism among older patients was 64% and 60% at 1 and 3 years, respectively, and was similar to that of younger patients. Increased B regulatory cells potentially contributed to low alloreactivity and mutual donor-recipient tolerance in older patients. Effect of comorbidities rather than age alone may be a more important determinant of suitability for FCC HSCT in older patients.
- Published
- 2019
48. PH-0329 Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network
- Author
-
E. Alexander, Reuben Benjamin, J. Summers, M. Cuadrado, I. Vasiliadou, J.L. Brady, C. Gillham, Robin Sanderson, A. Kuhnl, O. Evans, Victoria Potter, N. Mikhaeel, Piers Em Patten, A. Bates, and T. Ajithkumar
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,medicine.medical_treatment ,medicine.disease ,Surgery ,Radiation therapy ,Apheresis ,Oncology ,Refractory ,Internal medicine ,Cohort ,Toxicity ,medicine ,Vomiting ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,business ,Progressive disease - Abstract
Purpose or Objective CD19 CAR-T therapy is the most effective salvage treatment for relapsed/refractory DLBCL. However the manufacture of CAR-T cells takes several weeks and patients (pts) are at risk of progression during this time and usually require some form of bridging therapy to contain their disease. Radiotherapy (RT) is an attractive bridging option, as the chance of response to further conventional cytotoxic therapy is low. RT is generally delivered in the window between apheresis and infusion and requires careful scheduling. The aim of this study is to evaluate the feasibility, toxicity and early outcome of bridging RT in a cohort of pts undergoing CAR-T therapy for DLBCL. Materials and Methods This was a prospective analysis of pts receiving bridging RT since the start of CAR-T programme at our institution. We collected data on pt demographics, disease and RT details, as well as outcomes including early response, relapse, survival and toxicity. Results (Table presented.) Between April 2019 & January 2021 a total of 27 pts have received bridging RT. Of these 23 have been infused (1 not infused due to COVID19, 1 due to cardiac function & 2 pending). The CAR-T therapy was delivered in 1 Haematology Institution, but bridging RT in 9 different referring centres. Pt and disease characteristics and RT details are shown in table 1. The median time from CT planning scan to start of RT was 10 days (4-42). The median time between apheresis and start of RT was 5 days (-37-21;3 patients received RT prior to apheresis at -37,-35 &-29 days) and median time between end of RT and CAR-T infusion was 19 days (10-116). No pts were delayed due to RT toxicity. Toxicity data was available for 22 pts. 10 (45.5%) reported no toxicity. Only 1 pt had grade 3 toxicity (vomiting & diarrhoea) and RT was stopped. The most common toxicities were skin reaction (n=5) & fatigue (n=4). 25/27 (92.6%) pts underwent a PET-CT between bridging RT & infusion. In 22 (88%) pts there was response in treatment field (CMR=2, PMR=20). In 13 (59.1%) of those pts there was evidence of progressive disease (PD) outside the field, but none were prevented from receiving CAR-T infusion due to PD. With median FU of 8.8 (0.6-20.6) months from date of CAR-T infusion, 12/ 23 (52.2%) infused pts have relapsed, (2 infield, 5 out of field, 5 in both) with a local control rate of 69.6%;CMR (12;52.2%) and PMR (4;17.4%). 7 pts have died since infusion, 6 due to PD and 1 due to sepsis. Median PFS was 5.1 months (95% CI 0.0-11.9 months) and median OS 17.8 months (95% CI 12.7-22.9 months). 1 pt had infusion delayed due to COVID19 infection and died of PD. Conclusion RT was a safe and effective bridging option in this cohort of DLBCL pts pre CAR-T therapy. With close collaboration between Haematologists and Radiation Oncologists, it is possible to deliver a course of radical dose RT in the narrow window between apheresis and infusion, even across a wide geographical network. Further work is required to determine which pts benefit most from bridging RT and the optimal dose and schedule.
- Published
- 2021
49. COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
- Author
-
María Suárez-Lledó, María-José Jiménez, Zoraida Mesa Morales, Gloria Tridello, Beatriz Aguado, Nicolaas Schaap, Jose Luis Piñana Sanchez, Nina Knelange, Dries Deeren, Rodrigo Martino Bufarull, Ipek Yonal-Hindilerden, Maria Laura Fox, Angel Cedillo, Kim Orchard, Nicolaus Kröger, Claudia Crippa, Daniele Vallisa, Per Ljungman, Célestine Simand, Luisa Sisinni, Rafael F. Duarte, Safiye Koculu, Malgorzata Mikulska, Yves Beguin, Stephan Mielke, Jose Luiz Lopez Lorenzo, Fabio Ciceri, John A. Snowden, Lucía López Corral, Victoria Potter, Jan Styczyński, Juan Carlos Vallejo Llamas, Mi Kwon, Rocio Parody Porras, Javier Lopez Jimenez, Rafael de la Cámara, Aliénor Xhaard, and Anna De Grassi
- Subjects
medicine.medical_specialty ,education.field_of_study ,Coronavirus disease 2019 (COVID-19) ,Performance status ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Immunology ,Population ,Immunosuppression ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Biochemistry ,Transplantation ,Internal medicine ,Medicine ,721.Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities ,Risk factor ,business ,education - Abstract
COVID-19 is a severe infectious complication in patients with underlying medical conditions such as having undergone hematopoietic stem cell transplantation (HCT). This prospective survey reports outcome on 272 COVID-19 patients from 19 countries having undergone allogeneic (n = 175) or autologous (n = 97) HCT reported to the EBMT registry or to the GETH. All patients had the diagnosis of SARS-CoV-2 documented by PCR. Patients were included in this analysis if COVID-19 diagnosis was before April 10, 2020. The overall survival was estimate by using the Kaplan Meier methods, considering the death due to any cause as an event and the time from COVID-19 infection to the latest follow-up as survival time; difference between groups were tested by the log-rank test. Univariate and multivariate risk factor analysis for overall survival were performed with the Cox regression model. The median age was 54.4 years (1.0 - 80.3) for allogeneic and 60.9 years (7.7 - 73.4) for autologous HCT patients. 20 patients were children (< 18 years of age; median age 11.3 (1.0 - 16.9)). The median time from HCT to diagnosis of COVID-19 was 13.7 months (0.2 - 254.3) in allogeneic and 25.0 months (-0.9 - 350.3) in autologous recipients. Lower respiratory tract disease (LRTD) developed in 84.8% and 21.5% were admitted to an intensive care unit (ICU). At the time of analysis, 68/238 (28.6%) patients had died (47/155 allogeneic patients; 21/83 autologous patients). No follow-up had been received on 34 patients. The median time from infection to death was 19 days (0-102). Five patients were reported to have other primary causes of death than COVID-19. Of the patients reported to be alive, the median follow-up was 44 days. 144 (84.7%) patients (93 allogeneic; 51 autologous) had virologic resolution of the COVID-19 infection having at least one negative PCR. 26 patients were alive and known to be still COVID-19 positive (15 allogeneic; 11 autologous). For 34 patients the resolution status was unknown. Factors influencing the likelihood of resolution in multivariate analysis were underlying diagnosis (p=.01) and longer time from transplant to diagnosis of COVID-19 (p=.035). Overall survival at 6 weeks from COVID-19 diagnosis was 76.8% and 83.8% in allogeneic and autologous HCT recipients (p =ns), respectively (figure 1). Children (n=20) tended to do better with a 6-week survival of 95.0% although the difference was not significantly different (p =.12). In multivariate analysis of the total population older age (HR 1.26; 95% CI 1.05 - 1.51; p = .01) increased the risk and better performance status decreased the risk for fatal outcome (HR 0.79; 95% CI 0.69 - 0.90; p = .0003). The same factors had significant impact on overall survival in allogeneic HCT recipients (age HR 1.28; 95% CI 1.05 - 1.55; p=.01; performance status HR 0.79; 95% CI 0.68 - 0.92); p=.002) while only age impacted survival among autologous HCT patients (data not shown). Other transplant factors such as underlying diagnosis, time from HCT to diagnosis of COVID-19, graft-vs-host disease, or ongoing immunosuppression did not have a significant impact on overall survival. We conclude that HCT patients are at an increased risk compared to the general population to develop LRTD, require admission to ICU, and have increased mortality in COVID-19. Figure 1 Disclosures Duarte: Incyte Corporation: Other: Has received speaker and advisor fees. Kwon:Jazz: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. Mielke:Novartis: Honoraria, Other: received via my institution, Speakers Bureau; Celgene/BMS: Honoraria, Other: received via my institution , Speakers Bureau; Bellicum: Honoraria, Other: received via my institution, Speakers Bureau; Kite/Gilead: Honoraria, Other: received via my institution , Speakers Bureau; Miltenyi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: received via my institution , Speakers Bureau; KIADIS Pharma: Honoraria, Other: received via my institution , Speakers Bureau; DNA Prime: Honoraria, Other: received via my institution , Speakers Bureau. López Jiménez:MSD: Speakers Bureau; Roche: Research Funding, Speakers Bureau; Takeda: Speakers Bureau; Janssen: Research Funding, Speakers Bureau; Abbvie: Research Funding, Speakers Bureau; Gilead: Research Funding, Speakers Bureau.
- Published
- 2021
50. Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation : a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT
- Author
-
Zinaida Peric, Nicolaus Kröger, Aleksandar Radujkovic, Henrik Sengeloev, Grzegorz Helbig, Christian Koenecke, Victoria Potter, Dietrich W. Beelen, Hélène Schoemans, Christophe Peczynski, Gérard Socié, John A. Snowden, Nigel H. Russell, Charles Crawley, Olaf Penack, Jürgen Finke, Emmanuelle Polge, Donald Bunjes, Adrian Bloor, and Grzegorz W. Basak
- Subjects
Transplantation ,medicine.medical_specialty ,Matched Pair Analysis ,Transplantation Conditioning ,business.industry ,medicine.medical_treatment ,Matched-Pair Analysis ,MEDLINE ,Hematopoietic Stem Cell Transplantation ,Medizin ,Hematology ,Hematopoietic stem cell transplantation ,medicine.disease ,Inflammatory Bowel Diseases ,Inflammatory bowel disease ,Treatment Outcome ,Transplant complications ,Internal medicine ,Medicine ,Humans ,Inflammatory Bowel Diseases / therapy ,business ,Retrospective Studies - Abstract
in press
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.